2 false false false false false false false false false false true false false false false false false No description of principal activity 2024-04-01 Sage Accounts Production Advanced 2024 - FRS102_2024 6,962,976 6,962,976 6,962,976 xbrli:pure xbrli:shares iso4217:GBP 07502260 2024-04-01 2025-03-31 07502260 2025-03-31 07502260 2024-03-31 07502260 2023-04-01 2024-03-31 07502260 2024-03-31 07502260 2023-03-31 07502260 bus:Director1 2024-04-01 2025-03-31 07502260 bus:Director2 2024-04-01 2025-03-31 07502260 core:WithinOneYear 2025-03-31 07502260 core:WithinOneYear 2024-03-31 07502260 core:ShareCapital 2025-03-31 07502260 core:ShareCapital 2024-03-31 07502260 core:RetainedEarningsAccumulatedLosses 2025-03-31 07502260 core:RetainedEarningsAccumulatedLosses 2024-03-31 07502260 core:CostValuation core:Non-currentFinancialInstruments 2025-03-31 07502260 core:Non-currentFinancialInstruments 2025-03-31 07502260 core:Non-currentFinancialInstruments 2024-03-31 07502260 bus:SmallEntities 2024-04-01 2025-03-31 07502260 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 07502260 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 07502260 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 07502260 bus:FullAccounts 2024-04-01 2025-03-31 07502260 bus:Director1 1 2024-04-01 2025-03-31 07502260 core:AllAssociates 2024-04-01 2025-03-31
COMPANY REGISTRATION NUMBER: 07502260

DMC Medical Ltd

Filleted Unaudited Financial Statements

31 March 2025

DMC Medical Ltd

Financial Statements

Year ended 31 March 2025

Contents | Page

Statement of financial position | 1

Notes to the financial statements | 3

DMC Medical Ltd

Statement of Financial Position

31 March 2025

| 2025 | 2024
Note | £ | £

Fixed assets

Investments | 5 | 6,962,976 | 6,962,976

Current assets

Debtors | 6 | 1,197,101 | 1,158,084
Cash at bank and in hand | 167 | 598
| ------------ | ------------
| 1,197,268 | 1,158,682

Creditors: amounts falling due within one year | 7 | 5,519,516 | 5,479,197
| ------------ | ------------
Net current liabilities | 4,322,248 | 4,320,515
| ------------ | ------------
Total assets less current liabilities | 2,640,728 | 2,642,461
| ------------ | ------------
Net assets | 2,640,728 | 2,642,461
| ------------ | ------------

Capital and reserves

Called up share capital | 2 | 2
Profit and loss account | 2,640,726 | 2,642,459
| ------------ | ------------
Shareholders funds | 2,640,728 | 2,642,461
| ------------ | ------------

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.
For the year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .

DMC Medical Ltd

Statement of Financial Position (continued)

31 March 2025
These financial statements were approved by the board of directors and authorised for issue on 14 January 2026 , and are signed on behalf of the board by:

Mr A K Gupta | Mr R Gupta
Director | Director

Company registration number: 07502260

DMC Medical Ltd

Notes to the Financial Statements

Year ended 31 March 2025
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 60 Chadwick Road, Peckham, London, SE15 4PU, United Kingdom.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Going concern
After making appropriate enquiries, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future for at least one year from the date of the financial information. For these reasons they continue to adopt the going concern basis in preparing the company's financial information.
Consolidation
The company has taken advantage of the option not to prepare consolidated financial statements contained in Section 398 of the Companies Act 2006 on the basis that the company and its subsidiary undertakings comprise a small group.
Investments
Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses.
Impairment of fixed assets
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.
Financial instruments
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account in other administrative expenses. Loans and borrowings are initially recognised at the transaction price including transaction costs. Subsequently, they are measured at amortised cost using the effective interest rate method, less impairment. If an arrangement constitutes a finance transaction it is measured at present value.
4. Employee numbers
The average number of persons employed by the company during the year amounted to 2 (2024: 2 ).
5. Investments

| Shares in group undertakings
| £
Cost |
At 1 April 2024 and 31 March 2025 | 6,962,976
| ------------
Impairment |
At 1 April 2024 and 31 March 2025 | –
| ------------

Carrying amount |
At 31 March 2025 | 6,962,976
| ------------
At 31 March 2024 | 6,962,976
| ------------

6. Debtors

| 2025 | 2024
| £ | £
Amounts owed by group undertakings and undertakings in which the company has a participating interest | 920,000 | 920,000
Other debtors | 277,101 | 238,084
| ------------ | ------------
| 1,197,101 | 1,158,084
| ------------ | ------------

7. Creditors: amounts falling due within one year

| 2025 | 2024
| £ | £
Amounts owed to group undertakings and undertakings in which the company has a participating interest | 5,426,573 | 5,426,573
Corporation tax | 40,319 | –
Other creditors 1 - desc in a/cs | 51,134 | 51,134
Other creditors | 1,490 | 1,490
| ------------ | ------------
| 5,519,516 | 5,479,197
| ------------ | ------------

8. Directors' advances, credits and guarantees
At the balance sheet date the company was owed £115,607 (2024: £115,607) by a director.
9. Related party transactions
At the balance sheet date the company was owed £920,000 (2024: £920,000) from companies owned within common control. At the balance sheet date the company owed £5,426,573 (2024: £5,426,573) to companies owned within common control.